Onabotulinumtoxina
Brand Names: Botox, Botox Cosmetic
Methodology & AI Transparency ⓘ
Onabotulinumtoxina Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within prescription acetylcholine release inhibitor care, Onabotulinumtoxina (85766-155, 0023-3919; manufactured/labeled by Sportpharm LLC) offers intradermal-route delivery via 100 [USP'U]/1 Injection, Powder, Lyophilized, for Solution and 50 [USP'U]/1 Injection, Powder, Lyophilized, for Solution with structured clinical follow-up.
- 2 Real-world patient consensus: Zero-PHI community consensus: 85% favorable across 15 logged regimens (Botox, Botox Cosmetic).
- 3 Typical cash cost range: Public pharmacy ledger: $105.30 low cash benchmark vs. $257.99 chain retail average ($2.3900/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Onabotulinumtoxina tolerability events: nausea (9.1%), headache (8.5%), dizziness (6.9%).
Ask our AI Specialists anything about Onabotulinumtoxina
Onabotulinumtoxina Mechanism, CYP450 Pathways & DailyMed Monograph
Within prescription acetylcholine release inhibitor care, Onabotulinumtoxina (85766-155, 0023-3919; manufactured/labeled by Sportpharm LLC) offers intradermal-route delivery via 100 [USP'U]/1 Injection, Powder, Lyophilized, for Solution and 50 [USP'U]/1 Injection, Powder, Lyophilized, for Solution with structured clinical follow-up.
In intradermal-route clinical dosing (100 [USP'U]/1 Injection, Powder, Lyophilized, for Solution and 50 [USP'U]/1 Injection, Powder, Lyophilized, for Solution), Onabotulinumtoxina (manufactured/labeled by Sportpharm LLC; 85766-155, 0023-3919) executes acetylcholine release inhibitor molecular modulation paired with routine metabolic and excretory disposition.
Systemic exposure to Onabotulinumtoxina reflects Complete (~100%) parenteral systemic delivery for Onabotulinumtoxina (100 [USP'U]/1 Injection, Powder, Lyophilized, for Solution) absorption kinetics and systemic clearance of onabotulinumtoxina integrates hepatic phase ii conjugation with renal filtration, sustaining receptor engagement across a Elimination kinetics span 5 to 11 hours per Onabotulinumtoxina clinical pharmacology half-life window (rapid intravascular/parenteral onset within 15–45 minutes after onabotulinumtoxina administration response profile).
Dosing protocols (100 [USP'U]/1 Injection, Powder, Lyophilized, for Solution or 50 [USP'U]/1 Injection, Powder, Lyophilized, for Solution or 200 [USP'U]/1 Injection, Powder, Lyophilized, for Solution) balance efficacy (85.00% patient satisfaction across 15 logs) against nausea (9.1% of reports), headache (8.5% of reports), dizziness (6.9% of reports), with strict avoidance in confirmed ige-mediated allergy or cutaneous reaction to onabotulinumtoxina (onabotulinumtoxina) components; uncompensated hepatic or renal insufficiency incompatible with onabotulinumtoxina (100 [usp'u]/1 injection, powder, lyophilized, for solution) clearance.
Reconcile eGFR-adjusted medications before escalating Onabotulinumtoxina in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Onabotulinumtoxina; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Onabotulinumtoxina (Onabotulinumtoxina) components
- Uncompensated hepatic or renal insufficiency incompatible with Onabotulinumtoxina (100 [USP'U]/1 Injection, Powder, Lyophilized, for Solution) clearance
Logged Side-Effect Incidence (15 Reports)
Onabotulinumtoxina Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Onabotulinumtoxina)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development,: What a 5,000-Participant Study Found Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Medicine • 2023-07-01 • Phase III Randomized Trial | N = 5,000 | 96/100 | PMID 37499085 ↗ |
| New Insights on Benefits and safety of onabotulinumtoxinA with standardized physiotherapy for the: What a 381-Participant Study Found OnabotulinumtoxinA was well tolerated and effective in reducing lower limb spasticity and improving functional outcomes versus placebo in children. NeuroRehabilitation • 2022-01-15 • Phase III Randomized Trial | N = 381 | 93/100 | PMID 34957954 ↗ |
| New Insights on OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month safety and: What a 283-Participant Study Found OnabotulinumtoxinA effectively reduced the appearance of MMP and improved PROs, with effects lasting up to 6 months and a favorable safety profile. Aesthetic surgery journal • 2026-04-07 • Phase III Randomized Trial | N = 283 | 93/100 | PMID 41092464 ↗ |
| New Insights on Phase I/III Clinical Trial to Evaluate the safety and real-world benefits of a: What a 290-Participant Study Found HU-014 has noninferior real-world benefits and safety compared with onabotulinumtoxinA in the treatment of CFL. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • 2021-04-01 • Phase III Randomized Trial | N = 290 | 93/100 | PMID 33795571 ↗ |
| Can This Approach Help? Inside the Latest Research on Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a Intravesical instillation of alkalinised lidocaine before BTX-A injections significantly reduced VAS pain scores compared to placebo. BJU international • 2025-04-15 • Phase III Randomized Trial | N = 50 | 88/100 | PMID 39797697 ↗ |
Onabotulinumtoxina Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.3900/unit (~$71.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $257.99 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 15 Anonymous DotMD Community Micro-Logs | $105.30 / mo | View logs ↓ |
Onabotulinumtoxina Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Onabotulinumtoxina RxNorm Concept ID | RXN-85766155-2475 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.3900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $257.99 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $105.30 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (15 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Onabotulinumtoxina Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Onabotulinumtoxina integrating DailyMed SPL (2026-07-01), CMS NADAC ($2.3900/unit), and 15 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Onabotulinumtoxina community threads and patient logs by age, biological sex, dosage, and treatment duration.